We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.
Currently, GILD is a #4 (Sell) on the Zacks Rank, and earnings estimate revision activity is trending downwards for the foreseeable future, as earnings growth also looks to be on the decline.
Gilead:
Beat earnings estimates. The biopharmaceutical giant reported non-GAAP earnings of $1.78 per share, coming in above the Zacks Consensus Estimate of $1.70 per share. Net income was $2.34 billion for the quarter.
Beat revenue estimates. The company saw revenue figures of $5.95 billion, beating our consensus estimate of $5.78 billion.
Total product sales for the fourth quarter came to $5.8 billion, a much lower figure compared to the $7.2 billion in the same period in 2016. Breaking it down by region, product sales were $4.1 billion in the U.S., $1.1 billion in Europe, and $553 million in other locations.
Antiviral product sales, which include the sales of Gilead’s HIV, chronic hepatitis B (HBV), and chronic hepatitis C (HCV) products, were $5.2 billion in Q4 compared to $6.6 billion in the same period last year.
Looking at the full year 2018, Gilead expects net products sales in the range of $20 billion to $21 billion, and non-GAAP product gross margin in the range of 85% to 87%.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline
Gilead Sciences (GILD - Free Report) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.
Currently, GILD is a #4 (Sell) on the Zacks Rank, and earnings estimate revision activity is trending downwards for the foreseeable future, as earnings growth also looks to be on the decline.
Gilead:
Beat earnings estimates. The biopharmaceutical giant reported non-GAAP earnings of $1.78 per share, coming in above the Zacks Consensus Estimate of $1.70 per share. Net income was $2.34 billion for the quarter.
Beat revenue estimates. The company saw revenue figures of $5.95 billion, beating our consensus estimate of $5.78 billion.
Total product sales for the fourth quarter came to $5.8 billion, a much lower figure compared to the $7.2 billion in the same period in 2016. Breaking it down by region, product sales were $4.1 billion in the U.S., $1.1 billion in Europe, and $553 million in other locations.
Antiviral product sales, which include the sales of Gilead’s HIV, chronic hepatitis B (HBV), and chronic hepatitis C (HCV) products, were $5.2 billion in Q4 compared to $6.6 billion in the same period last year.
Looking at the full year 2018, Gilead expects net products sales in the range of $20 billion to $21 billion, and non-GAAP product gross margin in the range of 85% to 87%.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead Sciences is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>